Follow on Google News News By Tag * Therapeutic Antibodies * Monoclonal Antibodies * Antibody Patents * Monoclonal Antibody Patents * Humira * More Tags... Industry News News By Location Country(s) Industry News
Follow on Google News | New Report Analyzes the Potential of Therapeutic Monoclonal Antibodies in IndiaResearch firm IMARC Group expects this market to grow at a CAGR of around 26% during 2013-2016, according to its latest report entitled “Indian Monoclonal Antibodies Market Report & Forecast: 2012-2016”.
By: IMARC Group According to an analyst at IMARC Group, “India’s poor historical track record in Intellectual property protection has resulted in many Indian companies acquiring strong reverse engineering skills. The Indian generic industry provides generic drugs not only to India but to the entire world. India currently has more FDA approved manufacturing facilities than any other country outside the US. Globally there are only 2 approved biosimilar monoclonal antibodies with Reditux (Rituximab) (developed and manufactured by Dr. Ready’s, an Indian generic manufacturer) Key Aspects Analyzed in this Report: • Understanding the strengths, weaknesses, opportunities and challenges in the Indian monoclonal antibodies market • Understanding the technological considerations and regulatory factors in the Indian monoclonal antibodies market • Evaluation and identification of monoclonal antibodies based on the sources from which they are derived and on the targets against which they act • Understanding the key regulations for registering, manufacturing and importing monoclonal antibodies in India • Evaluating the patent details of all globally marketed monoclonal antibodies in India, US and Europe • Identifying the patentee name and patent numbers of all in-market monoclonal antibodies in India, US and Europe • Identifying the monoclonal antibodies that are patent protected in India, US and Europe and those that are not • Estimating the patent expiries of various monoclonal antibodies in India, US and Europe • Comprehensive situation analysis of the Indian monoclonal antibodies market • Analyzing current and future sales of monoclonal antibodies in India • Identifying all globally launched monoclonal antibodies and understanding their performance and launch status in India • Analyzing the global and Indian monoclonal antibodies market by Indication • Evaluation of the top selling monoclonal antibodies • Key biosimilar antibody development programmes in India and abroad Table of Contents 1 Market Definitions & Methodology 2 Executive Summary 3 Therapeutic Antibodies Market in India 3.1 Industry Analysis 3.1.1 Strengths 3.1.2 Weaknesses 3.1.3 Opportunities 3.1.4 Threats 3.2 Technological & Regulatory Assessment 3.2.1 Technological Assessment 3.2.2 Regulatory Assessment 3.3 Patent Details of Various Monoclonal Antibodies: US, Europe & India 3.4 Market Analysis 3.4.1 Current & Future Sales Trends 3.4.2 Sales Breakup by Molecule 3.4.3 Sales by Indication 3.5 Evaluation of Top Monoclonal Antibodies 3.5.1.1 Avastin 3.5.1.2 Herceptin 3.5.1.3 Rituxan/Mabthera 3.5.1.4 Remicade 3.5.1.5 Humira 3.6 Biosimilar Case Studies 5.6.1 Reditux 5.6.2 Grafeel 3.7 Key Indian & Foreign Biosimilar Antibody Development Programmes To buy the complete report or to get a free sample, please contact: IMARC Group Asia Email: apac@imarcgroup.com Phone: +91-120-415- IMARC Group North America Email: america@ Phone: +1-631-791-1145 IMARC Group Europe, Middle East & Africa Email:ema@imarcgroup.com Phone: +44-702-409- To know more please visit: http://www.imarcgroup.com/ End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|